Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

tive household survey, which used a lay-administered diagnostic interview to assess a wide range of DSM-IV disorders. ADHD is a neurobiological disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

For further information please contact:

Porter Novelli for Shire

Sherry Goldberg

212.601.8279

917.923.4010 (mobile)

sherry.goldberg@porternovelli.com

Michelle Park

212.601.8248

212.729.4577 (mobile)

michelle.park@porternovelli.com

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... SAN JOSE, Calif. , Oct. 1, 2014  SI-BONE, ... the iFuse Implant System, ® a minimally invasive surgical ... sacroiliac (SI) joint, today announced the expansion of its European ... of Mr. Eric Schaber as General Manager, Germany.  ... , currently vice president of Europe , ...
(Date:10/1/2014)... Suisse, October 1, 2014 ... dans le domaine de l,analyse des données issues ... une solution de diagnostic in vitro (IVD) du ... complète de la mucoviscidose dans un seul essai ... caractériser tous les types de variantes par l,intermédiaire ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
... 2011 BioMedix™, a leader in providing integrated Health ... a U.S. Patent recognizing its innovative solutions and methods ... On July 19, 2011, the United States Patent & ... and Method for Testing for Cardiovascular Disease," crediting BioMedix™ ...
... 2011 On the 1-year anniversary of Congress approving ... of Columbia Patients, Cooperative (DCPC), a District-based non-profit organization ... Americans for Safe Access, will hold a press conference ... of the John A. Wilson Building, 1350 Pennsylvania Ave. ...
Cached Medicine Technology:BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method 2DC Patients' Cooperative to Announce Operations Hiatus Until City Shows Leadership 2
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post ... , Senior citizens can purchase a joint life ... ones. A joint policy is cheaper, but will only ... , Life insurance can be used to cover important ... purchased online, as the application process is simple and ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater Toronto Area’s ... is announcing a discounted cost on Botox units, which ... doing this because we want to give as many ... in Toronto,” says Dr. Brian Sieber, founder of Anti ... Clinic, including laser facials, genesis laser facials, chemical ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... the Need for Location-Based Mobile Convergence, Solutions for Enterprises by ... ... Winner, SUNNYVALE, Calif., March 13 Agito Networks, Inc., ... a 2008 VON Magazine Innovator Award, which is awarded,to innovative companies that ...
... Successful Execution of Partnership Strategy Provides Nearly $450 Million ... Cash and Committed Cash * 2008 Projected Net Operating Loss ... Greater than $450 Million * Conference Call Webcast Thursday, March 13, 08:30 a.m. ... http://www.isispharm.com , CARLSBAD, Calif., March ...
... March 13 DKMS is proud to announce that ... Gala" on,Wednesday, May 7th, 2008 at Capitale in New ... to raise money and awareness for DKMS, the,world,s largest ... which has helped facilitate more than 13,000 transplants., ...
... its ... 6th FDA approval, CARLSBAD, ... has received FDA approval on its new,over-the-counter light therapy device, Omnilux ... Omnilux New-U has been clinically proven to reduce periorbital wrinkles,and ...
... Compromises Are Not Good Enough, WASHINGTON, March 12 ... tightening of the,health-based National Ambient Air Quality Standard for ... but we cannot. The standard announced,today, although an improvement, ... Act. We are unable to celebrate half measures when ...
... The Providence,Service Corporation (Nasdaq: PRSC ) today announced ... shares of its common stock on Form S-3,with the ... will file the proposed shelf registration statement immediately,following the ... the Year Ended,December 31, 2007; however, it has no ...
Cached Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 4Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 5Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 6Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 7Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 8Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 9Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 10Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 11Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 12Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 13Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 14Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 15Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 16Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 17Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 18Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 19Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 20Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 21Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 22Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 23Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 24Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 25Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 26Health News:Super Model Cindy Crawford will be Honored at DKMS 'Linked Against Leukemia Gala' on May 7th at Capitale 2Health News:Omnilux New-U(TM) Hand-Held Device Receives FDA Approval 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 3Health News:Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement 2
... For the quantitative determination ... human serum. Progesterone ... the principle of competitive ... the test specimen and ...
... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
... platelet incubators provide accurate and stable ... incorporated all of the same alarm, ... found in the Labcold BS Blood ... of product security. An independent 7 ...
The PC4200h is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
Medicine Products: